These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. [Influence of genetic mutations on clinical presentation of subretinal neovascularization. Report 2: The impact of HTRA and VEGF genes polymorphism]. Budzinskaia MV; Pogoda TV; Strelkova ID; Chikun EA; Shchegoleva IV; Kazarian ÉÉ; Galoian NS Vestn Oftalmol; 2011; 127(4):9-16. PubMed ID: 21882634 [TBL] [Abstract][Full Text] [Related]
27. Polymorphisms in C2, CFB and C3 are associated with progression to advanced age related macular degeneration associated with visual loss. Francis PJ; Hamon SC; Ott J; Weleber RG; Klein ML J Med Genet; 2009 May; 46(5):300-7. PubMed ID: 19015224 [TBL] [Abstract][Full Text] [Related]
28. Association between polymorphism rs11200638 in the HTRA1 gene and the response to anti-VEGF treatment of exudative AMD: a meta-analysis. Zhou YL; Chen CL; Wang YX; Tong Y; Fang XL; Li L; Wang ZY BMC Ophthalmol; 2017 Jun; 17(1):97. PubMed ID: 28637435 [TBL] [Abstract][Full Text] [Related]
32. Photodynamic therapy combined with intravitreal injection of vascular endothelial growth factor antibody for polypoidal choroidal vasculopathy. Moon SW; Kim MS; Kim ES; Yu SY; Kwak HW Ophthalmologica; 2011; 225(3):169-75. PubMed ID: 21273795 [TBL] [Abstract][Full Text] [Related]
33. Efficacy of vitrectomy and inner limiting membrane peeling in age-related macular degeneration resistant to anti-vascular endothelial growth factor therapy, with vitreomacular traction or epiretinal membrane. Kimura S; Morizane Y; Toshima S; Hosogi M; Kumase F; Hosokawa M; Shiode Y; Fujiwara A; Shiraga F Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1731-6. PubMed ID: 26951250 [TBL] [Abstract][Full Text] [Related]
34. Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis. Wu M; Xiong H; Xu Y; Xiong X; Zou H; Zheng M; Wang X; Zhou X Br J Ophthalmol; 2017 Jul; 101(7):976-984. PubMed ID: 28400373 [TBL] [Abstract][Full Text] [Related]
35. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration. Lee SJ; Koh HJ Ophthalmology; 2011 Jan; 118(1):101-10. PubMed ID: 20678805 [TBL] [Abstract][Full Text] [Related]
36. Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration. Krebs I; Glittenberg C; Ansari-Shahrezaei S; Hagen S; Steiner I; Binder S Br J Ophthalmol; 2013 Nov; 97(11):1443-6. PubMed ID: 23966368 [TBL] [Abstract][Full Text] [Related]
37. Intravitreal anti-VEGF therapy for macular radiation retinopathy: a 10-year study. Finger PT; Chin KJ; Semenova EA Eur J Ophthalmol; 2016; 26(1):60-6. PubMed ID: 26391167 [TBL] [Abstract][Full Text] [Related]
38. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program. Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658 [TBL] [Abstract][Full Text] [Related]
39. Antivascular endothelial growth factors in the treatment of macular oedema secondary to central retinal vein occlusion: a meta-analysis. Zhou S; Gao J; Xu X Clin Exp Ophthalmol; 2014; 42(7):637-49. PubMed ID: 24330277 [TBL] [Abstract][Full Text] [Related]
40. [The pharmacogenomics of CFH Y402H and wet age-related macular degeneration]. Chen LL; Chen YY Zhonghua Yan Ke Za Zhi; 2017 Feb; 53(2):144-147. PubMed ID: 28260367 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]